ValiRx gets rights to CRT's prostate cancer compound
Cancer Research UK's Cancer Research Technology Ltd. has licensed public biotech ValiRx PLC exclusive worldwide rights to develop and commercialize a peptide therapeutic aimed at hormone-resistant prostate cancer and other potential indications.
- Large Molecule
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com